Table 1.

mTOR inhibitors and their therapeutic importance.

Sr. No.	Name of mTOR Inhibitor	Therapeutic Importance	Reference
1	Rapamycin (Sirolimus)	Fungicidal characteristics First licensed immunosuppressant for solid organ transplant recipients Antiproliferative properties Anti-aging properties Anti-atherosclerotic properties	[80] [81] [82] [83]
2	Temsirolimus	Treat advanced Renal cancer	[77]
3	Everolimus	Treat Metastatic Renal cell carcinoma (Kidney cancer) Treat Advanced neuroendocrine pancreatic tumours	[84] [85] [86]
4	Ridaforolimus/Deforolimus	Sarcoma Breast cancer	[87] [88]
5	Zotarolimus	Antitumor activity	[89]
6	Torin 1	Suppress colon cancer cells	[90]
7	Torin 2	Antitumor activity	[91]
8	MLN0128	Advanced solid tumors	[92]
9	AZD2014 (Vistusertib)	Metastatic clear cell renal cancer	[92]
10	Voxtalisib (SAR24540; XL765)	non-Hodgkin lymphoma or chronic lymphocytic lymphoma that has relapsed or is refractory	[92]
11	Gedatolisib (PKI-587 PF05212384)	Recurrent endometrial cancer	[92]
12	Rapalink-1	Strong Anticancer properties Tumors resistant to 1st and 2nd generation mTOR inhibitors shrink in size.	[77]
13	Halitulin analog ICSN3250	It has the ability to compete with and interchange phospholipids acid in the mTOR FRB domain	[93]
14	LY3023414	It inhibits the PI3K/mTOR/DNA-PK pathway in tumor cells in vitro It has anti-tumor proliferation effect It causes prolonged reduction in endometrial cancer patients with phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1), phosphate, and PTEN mutations.	[94]
15	O SU-53	Inhibit thyroid cancer cell growth in vitro by activating AMPK to block the mTOR pathway or directly blocking the mTOR pathway.	[95]
16	OSI-027	Anticancer	[96]
17	C C-223	Anticancer	[97]
18	PKI-587	Gastroenteropancreatic Neuroendocrine tumor disease	[98]
19	INK-128	Inhibit angiogenesis and tumor growth in B-cell lymphoma Neuroblastoma Thyroid cancer cells Prostate cancer metastasis B-cell acute lymphoblastic leukemia Breast cancer	[99]
20	GSK2126458	Robust activity in cancer models	[100]
21	XL765	Glioblastoma development is inhibited by triggering ER stress-dependent apoptosis.	[101]
22	NVP-BEZ235	Cancer cell proliferation is inhibited by this compound	[102]
23	P529	Stops cancer cells from multiplying	[103]
24	JR-AB2-011	Anti-glioblastoma multiforme properties	[104]